ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Creative Commons License

Montalban X., Gold R., Thompson A. J., Otero-Romero S., Amato M. P., Chandraratna D., ...Daha Fazla

Multiple Sclerosis, cilt.24, sa.2, ss.96-120, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1177/1352458517751049
  • Dergi Adı: Multiple Sclerosis
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.96-120
  • Anahtar Kelimeler: Multiple sclerosis, guideline, disease-modifying therapies, GRADE methodology, DISEASE-MODIFYING DRUGS, SUBCUTANEOUS INTERFERON BETA-1A, PLACEBO-CONTROLLED TRIAL, RELEASE DIMETHYL FUMARATE, HIGH-YIELD PROCESS, DOUBLE-BLIND, GLATIRAMER ACETATE, PREGNANCY OUTCOMES, CONTROLLED PHASE-3, FOLLOW-UP
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.